Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders

Author(s): Marianna Mazza*, Giuseppe Marano, Gianandrea Traversi, Gabriele Sani, Luigi Janiri

Journal Name: CNS & Neurological Disorders - Drug Targets
(Formerly Current Drug Targets - CNS & Neurological Disorders)

Volume 19 , Issue 4 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Lumateperone (ITI-007) is a tosylate salt with binding affinities to receptors implicated in the therapeutic actions of antipsychotic medications, including the serotonin 5HT2A receptors, dopamine D2 and D1 receptors and the serotonin transporter. It has a unique mechanism of action because it simultaneously modulates serotonin, dopamine, and glutamate neurotransmission, implicated in serious mental illness. It can be considered a multi-target-directed ligand and a multifunctional modulator of serotoninergic system with possible precognitive, antipsychotic, antidepressant and anxiolytic properties. Lumateperone has been investigated as a novel agent for the treatment of schizophrenia, but it represents a new potential option for other psychiatric and neurological diseases, such as behavioural symptoms of dementia or Alzheimer’s disease, sleep disturbances, bipolar depression. Besides, it has demonstrated a favourable safety profile without significant extrapyramidal side effects, hyperprolactinemia or changes in cardiometabolic or endocrine factors versus placebo. Additional studies are warranted to confirm and examine the benefit of lumateperone and possible therapeutic targets. This paper is a comprehensive and thorough summary of the most important findings and potential future role of this particular compound in personalized treatments.

Keywords: Lumateperone, ITI-007, schizophrenia, Alzheimer`s disease, novel antipsychotics, personalized medicine.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [243 - 247]
Pages: 5
DOI: 10.2174/1871527319666200601145653
Price: $65

Article Metrics

PDF: 22